On February 20, 2020 Eureka Therapeutics, Inc., a clinical stage biotechnology company developing novel T cell therapies to treat solid tumors, reported that President and CEO Dr. Cheng Liu will be presenting at the 6th Annual Immuno-Oncology 360° Conference (IO360°) in New York on February 27, 2020 (Press release, Eureka Therapeutics, FEB 20, 2020, View Source [SID1234554574]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. Liu will be presenting the use of Eureka’s novel antibody-TCR receptor (ARTEMIS T cell) that has been engineered with a proprietary human TCR-mimic antibody to target an alpha fetoprotein (AFP)-peptide/HLA-A2 complex on HCC cancer cells.

Presentation Details

Title: Innovation Hour: New Scientific Frontiers in Cell Therapies for Solid Tumors

Speaker: Dr. Cheng Liu, President and CEO

Date: Thursday, February 27, 2020

Program: Cell & Gene Therapy Day, Track B

Time: 10:40 – 11:40 a.m. EST